FDA — authorised 28 August 2020
- Application: BLA761156
- Marketing authorisation holder: NOVO NORDISK INC
- Local brand name: SOGROYA
- Indication: SOLUTION — SUBCUTANEOUS
- Status: approved
🇺🇸 SOGROYA in United States
FDA authorised SOGROYA on 28 August 2020
Marketing authorisation
SOGROYA in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Other approved in United States
Frequently asked questions
Is SOGROYA approved in United States?
Yes. FDA authorised it on 28 August 2020.
Who is the marketing authorisation holder for SOGROYA in United States?
NOVO NORDISK INC holds the US marketing authorisation.